News Archives - Page 31 of 31

Toggle menu

HOME
ABOUT US
TECHNOLOGIES
- Our Technologies
- PIPELINE
INVESTORS
MEDIA
- Media
- Briefing recordings
CONTACT US

Category: News

Home > News

Prescient Therapeutics PTX Finance News Network

CEO Steven Yatomi-Clarke presentation

News 0

June 8, 2019 AUTHOR – enouvoteam

STOCK PRICE

ASX ANNOUNCEMENTS

Tags

AusBiz Biotech Dispatch BioWorld CGT Live Global Victoria Investing Kalkine Kalkine Media Market Herald Market Open Mirage News National Tribune Pitt Street Research Port Jackson Securities Prescient Therapeutics Proactive Investors Reach Markets Share Cafe ShareCafe Smallcaps Small Caps Stockhead Sub11 Switzer TechKnow Invest Roadshow The Australian The Australian Business Review The Market Herald The Sentiment Yahoo Finance

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies.

CONTACT

P: +61 3 9692 7222

F: +61 3 9077 9233

E: [email protected]

INVESTORS

This Investor Centre was built by Reach Markets.
Visit Reach Markets here

WordPress Theme built by Shufflehound.

Subscribe for updates

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.

A gross income of $250,000 or more per annum in each of the previous two financial years; or
Net assets of at least $2.5 million; and
A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)

Category: News

News

Prescient Therapeutics PTX Finance News Network

RECENT POSTS

Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research

Prescient Therapeutics: PTX-100 Phase 2 coming soon

Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director

Categories